Zevra Therapeutics completes Acer acquisition in $91m deal
by 
Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal.
Zevra has obtained access to Acer’s rare disease assets Olpruva, which is approved by the Food and Drug Administration (FDA) to treat specific urea cycle disorders, and Edsivo, currently being analysed in Phase III studies for vascular Ehlers-Danlos syndrome.
Zevra Therapeutics president and CEO Neil McFarlane stated: “The acquisition marks an exciting milestone for Zevra as we advance our mission to deliver therapies to the rare disease community.
“With our combined resources, expanded portfolio and expert capabilities, we have the opportunity to make a tremendous impact on the lives of people with serious rare diseases. We are excited about the opportunities ahead for patients and remain focused on executing our strategic priorities to create long-term shareholder value.”
The parties signed a definitive agreement for the merger in August 2023.
Visit our upcoming conference – https://virtueinsight.com/upcoming-conferences/